Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

823 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Publication Date timeline is not available.
Page 1
Final Results of a Randomized, Phase III Study of Rituximab With or Without Idelalisib Followed by Open-Label Idelalisib in Patients With Relapsed Chronic Lymphocytic Leukemia.
Sharman JP, Coutre SE, Furman RR, Cheson BD, Pagel JM, Hillmen P, Barrientos JC, Zelenetz AD, Kipps TJ, Flinn IW, Ghia P, Eradat H, Ervin T, Lamanna N, Coiffier B, Pettitt AR, Ma S, Tausch E, Cramer P, Huang J, Mitra S, Hallek M, O'Brien SM, Stilgenbauer S. Sharman JP, et al. Among authors: hallek m. J Clin Oncol. 2019 Jun 1;37(16):1391-1402. doi: 10.1200/JCO.18.01460. Epub 2019 Apr 17. J Clin Oncol. 2019. PMID: 30995176 Free PMC article. Clinical Trial.
Fludarabine in combination with alemtuzumab is effective and feasible in patients with relapsed or refractory B-cell chronic lymphocytic leukemia: results of a phase II trial.
Elter T, Borchmann P, Schulz H, Reiser M, Trelle S, Schnell R, Jensen M, Staib P, Schinköthe T, Stützer H, Rech J, Gramatzki M, Aulitzky W, Hasan I, Josting A, Hallek M, Engert A. Elter T, et al. Among authors: hallek m. J Clin Oncol. 2005 Oct 1;23(28):7024-31. doi: 10.1200/JCO.2005.01.9950. Epub 2005 Sep 6. J Clin Oncol. 2005. PMID: 16145065 Clinical Trial.
Fludarabine plus cyclophosphamide versus fludarabine alone in first-line therapy of younger patients with chronic lymphocytic leukemia.
Eichhorst BF, Busch R, Hopfinger G, Pasold R, Hensel M, Steinbrecher C, Siehl S, Jäger U, Bergmann M, Stilgenbauer S, Schweighofer C, Wendtner CM, Döhner H, Brittinger G, Emmerich B, Hallek M; German CLL Study Group. Eichhorst BF, et al. Among authors: hallek m. Blood. 2006 Feb 1;107(3):885-91. doi: 10.1182/blood-2005-06-2395. Epub 2005 Oct 11. Blood. 2006. PMID: 16219797 Free article. Clinical Trial.
Perspectives on the use of new diagnostic tools in the treatment of chronic lymphocytic leukemia.
Binet JL, Caligaris-Cappio F, Catovsky D, Cheson B, Davis T, Dighiero G, Döhner H, Hallek M, Hillmen P, Keating M, Montserrat E, Kipps TJ, Rai K; International Workshop on Chronic Lymphocytic Leukemia (IWCLL). Binet JL, et al. Among authors: hallek m. Blood. 2006 Feb 1;107(3):859-61. doi: 10.1182/blood-2005-04-1677. Epub 2005 Oct 13. Blood. 2006. PMID: 16223776 Free article. Review.
Autologous graft-versus-host disease-like syndrome after an alemtuzumab-containing conditioning regimen and autologous stem cell transplantation for chronic lymphocytic leukemia.
Zenz T, Ritgen M, Dreger P, Kröber A, Barth TF, Schlenk R, Böttcher S, Hallek MJ, Kneba M, Bunjes D, Döhner H, Stilgenbauer S. Zenz T, et al. Among authors: hallek mj. Blood. 2006 Sep 15;108(6):2127-30. doi: 10.1182/blood-2006-04-007898. Epub 2006 May 25. Blood. 2006. PMID: 16728696 Free article. Clinical Trial.
Due to low infection rates no routine anti-infective prophylaxis is required in younger patients with chronic lymphocytic leukaemia during fludarabine-based first line therapy.
Eichhorst BF, Busch R, Schweighofer C, Wendtner CM, Emmerich B, Hallek M; German CLL Study Group (GCLLSG). Eichhorst BF, et al. Among authors: hallek m. Br J Haematol. 2007 Jan;136(1):63-72. doi: 10.1111/j.1365-2141.2006.06382.x. Epub 2006 Nov 3. Br J Haematol. 2007. PMID: 17083342 Free article. Clinical Trial.
Health-related quality of life in younger patients with chronic lymphocytic leukemia treated with fludarabine plus cyclophosphamide or fludarabine alone for first-line therapy: a study by the German CLL Study Group.
Eichhorst BF, Busch R, Obwandner T, Kuhn-Hallek I, Herschbach P, Hallek M; German CLL Study Group. Eichhorst BF, et al. Among authors: hallek m. J Clin Oncol. 2007 May 1;25(13):1722-31. doi: 10.1200/JCO.2006.05.6929. Epub 2007 Mar 26. J Clin Oncol. 2007. PMID: 17389338 Clinical Trial.
Guidelines for the diagnosis and treatment of chronic lymphocytic leukemia: a report from the International Workshop on Chronic Lymphocytic Leukemia updating the National Cancer Institute-Working Group 1996 guidelines.
Hallek M, Cheson BD, Catovsky D, Caligaris-Cappio F, Dighiero G, Döhner H, Hillmen P, Keating MJ, Montserrat E, Rai KR, Kipps TJ; International Workshop on Chronic Lymphocytic Leukemia. Hallek M, et al. Blood. 2008 Jun 15;111(12):5446-56. doi: 10.1182/blood-2007-06-093906. Epub 2008 Jan 23. Blood. 2008. PMID: 18216293 Free PMC article.
Subcutaneous alemtuzumab in fludarabine-refractory chronic lymphocytic leukemia: clinical results and prognostic marker analyses from the CLL2H study of the German Chronic Lymphocytic Leukemia Study Group.
Stilgenbauer S, Zenz T, Winkler D, Bühler A, Schlenk RF, Groner S, Busch R, Hensel M, Dührsen U, Finke J, Dreger P, Jäger U, Lengfelder E, Hohloch K, Söling U, Schlag R, Kneba M, Hallek M, Döhner H; German Chronic Lymphocytic Leukemia Study Group. Stilgenbauer S, et al. Among authors: hallek m. J Clin Oncol. 2009 Aug 20;27(24):3994-4001. doi: 10.1200/JCO.2008.21.1128. Epub 2009 Jul 13. J Clin Oncol. 2009. PMID: 19597025 Clinical Trial.
823 results